Clinical Trial: SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109284) titled 'SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer' on July 31.

Brief Summary: This study aimed to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant therapy in early-stage high-risk ER+HER2- breast cancer patients.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: ER+HER2- Breast Cancer

Intervention: BIOLOGICAL: Sacituzumab tirumotecan

Sacituzumab tirumotecan 5 mg/kg, intravenously (iv), Q2W

BIOLOGICAL: Tagitanlimab

Tagitanlimab 900mg, intravenously (iv), Q2W

Recruitment Status: NOT_YET_RECRUITING

Sponsor: West China Hospital ...